TAS-116
- Generic Name
- TAS-116
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H26N8O
- CAS Number
- 1260533-36-5
- Unique Ingredient Identifier
- PLO044MUDZ
- Background
TAS-116 is under investigation in clinical trial NCT02965885 (A Study of TAS-116 in Patients With Solid Tumors).
- Associated Conditions
- -
- Associated Therapies
- -
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Brown University
- Target Recruit Count
- 27
- Registration Number
- NCT05655598
- Locations
- 🇺🇸
Lifespan Cancer Institute, Providence, Rhode Island, United States
AB122 Platform Study
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 715
- Registration Number
- NCT04999761
- Locations
- 🇯🇵
A site selected by Taiho Pharmaceutical Co., Ltd., Wakayama, Japan
A Study of TAS-116 in Patients With Solid Tumors
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT02965885
- Locations
- 🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇮🇹Regina Elena National Cancer Institute, Roma, Italy
🇬🇧The Christie NHS Foundation Trust Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath